PTO/SB/08 (2/92) OCI 3 0 2006 Sheet 1 of 8 3 Attorney's Pocket No. Application Serial No. **Form PTO-1449** 3910- ant(s) 09/904.786 39780-1618P2C47 INFORMATION DISCLOSURE STATEMENT ASHKENAZI, et al. **Group Art Unit:** Filing Date: 1646 (use several sheets if necessary) July 12, 2001 **U.S. PATENT DOCUMENTS** Subclass **Filing Date** Class Ref. Date Document No. Name Examiner (if appropriate) Initials No. 10/4/88 8/21/90 4.950,647 Robins et al. 1. 1/19/95 2. 7/15/97 5,648,376 Strobel et al. 5.801,193 Ojo-Amaize et al. 4/15/97 3. 9/1/98 6/7/95 10/6/98 5.817.306 Haskill et al. 4. 09/28/99 5.958.403 Storm, et al. 5. **FOREIGN PATENT DOCUMENTS Translation** Class Subclass Date Document No. Name Examiner Ref. YES NO **Initials** No. **OTHER DOCUMENTS** (including author, title, date, pertinent pages, etc.) Examiner Ref. Title Initials No. Abolhassani, M., "Antibacterial effect of borage (Echium amoenum) on Staphylococcus aureus," Brazilian Journal of NI 6. Infectious Diseases 8:382-385 (2004). Amirghofran, Z. et al., "Echium amoenum stimulate of lymphocyte proliferation and inhibit fo humoral antibody 7. synthesis," Im. J. Med. Sci. 25:119-124 (2000). Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a 8. mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells," J. Immunol. 161:6977-6984 (1998). Fung-Leung, et al., "Tepoxalin, A Novel Immunomodulatory Compound, Synergizes with CSA in Suppression of Graft-9. Versus-Host Reaction and Allogeneic Skin Graft Rejection", Transplantation, 60:362-368 (1995). Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived 10. sepsis by improving gut barrier function and modulating bacterial clearance," Annals of Surgery 220:68-76 (1994). Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor," 11. Science 264:965-968 (1994) Kasaian, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," Immunity 16:559-569 (2002). Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients 13. following subcutaneous application," Br. J. Clin. Pharmacol. 46:5-10 (1998). Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require

	<u> </u>				
EXAMINER:			DATE CONSIDERED); ,	
	VINA	•	101	M	151
EVALUATED. I	3 3 24 3 24 3 3 3 3 3 3 3 3 3 3 3 3		WALL MACH COO	Decision	line Absenceb

perforin but are independent of INF-y," J. Immunol. 171:608-615 (2003).

Immunol. 142:1834-1839 (1989).

J. Immunol. 153:1697-1706 (1994).

Sci. USA 86:5069-5073 (1989).

5094 (2005).

ugh the citation if not in EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. conformance and not considered. Include a copy of this form with next communication to applicant.

'If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," J.

Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN-y production."

Pahwa, R. et al. "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," Proc. Natl. Acad.

Patterson, S. et al., "Human invariant NKT cells are required for effective in vitro alloresponses," J. Immunol. 175:5087-

SV 2241833 v1

14.

15.

16.

17.

18.

OCT 3 0 2006

Form PTO-1449			Attomes/s Docket No. 39788-1618P2C47		Application Serial No. 09/904,786				
INFOR	RMATIO	N DISCLOSURE STATEME	NT	39780 1618P2C47 Applicant(s)		001004,100			
•					ASHKENAZ	l, et al			
				Filing Date:		Group Art Unit:			
(use several sheets if necessary)				July 12, 2001		1646			
m	19.	deficiency syndrome," Infe	ct. Immund	ol. <u>44</u> :339-343 (1984).	_	osexual men with acquired immune			
	20.	Santoli, D. et al., "Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules," <i>J. Immunol.</i> 137:400-407 (1986).							
·	21.	Shim, et al., "Immunosuppressive Effects of Tautomycetin <i>in vivo</i> and <i>in vitro</i> via T cell-specific Apoptosis Induction," <i>Proc. Natl. Acad. Sci.</i> , USA, 99(16):10617-10622 (2002).							
	22.	Tarr, P.E. et al., "Granulocyte-macrophage colony-stimulating factor and the immune system," <i>Med Oncol.</i> 13:133-140 (1996).							
	23.	galactosylceramide," <i>J. Immunol.</i> 163:2387-2391 (1999).							
V	24.	Tsavaris, N. et al., "Immune Br. J. Cancer <u>87</u> :21-27 (200	changes i 2).	in patients with advanced brea	st cancer unde	ergoing chemotherapy with taxanes,"			
				······································					
			· · · · · · · · · · · · · · · · · · ·	ı					
			•						
					•				
			 -		·				
						·			
	• • •								
			,		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
~						•			
	-		••	•					

_			L .				
	EXAMINER:		1	C 2	DATE CONSIDERED:		
		V	J. m		1/1/07		
ŀ	EXAMINER: Initial if ci	atior	tion considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
	conformance and not c	onsidered. Include a copy of this form with next communication to applicant.					
	"If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to						
	PTO in a prior applicati	on th	at is identical in	the statement and relied up	on for an earlier fillno date under 35 U.S.C. 6120. 37 C.F.R. 61.98 (d).		

SV 2241833 v1

000	3 0 2006	PTO/SB/08 (2/92 Sheet 3 of
Form PTO-1449	Attorney's Docket No. 39780-1618P2C47	Application Serial No. 09/904,786
INFORMATION DISCLOSURE STATEMENT	HABIT Applicant(s)	SHKENAZI, et al.
(use several sheets if necessary)	Filing Date: July 12, 2001	Group Art Unit: 1646
		·
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

					_			
-	EXAMINER:	N	^	DATE CONSIDERED:	T			
		U.	<u>C</u> h	1/1/27				
	EXAMINER: IntiaVifcitation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in							
	conformance and not considered. Include a copy of this form with next communication to applicant.							
	elf an association of and handed the anti-annial and anti-annial annial annial and anti-annial annial annia							

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2241833 v1